ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602) (Q37383950)

From Wikidata

Jump to navigation Jump to search

scientific article published on 11 October 2013

Language	Label	Description	Also known as
English	ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602)	scientific article published on 11 October 2013

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602) (English)

1 reference

Europe PubMed Central

20 August 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

metastatic melanoma

1 reference

based on heuristic

inferred from title

1

object named as

Ronald S Go

1 reference

Europe PubMed Central

20 August 2017

author name string

Sandra J Lee

2

1 reference

Europe PubMed Central

20 August 2017

Donghoon Shin

3

1 reference

Europe PubMed Central

20 August 2017

Steven M Callister

4

1 reference

Europe PubMed Central

20 August 2017

Dean A Jobe

5

1 reference

Europe PubMed Central

20 August 2017

Robert M Conry

6

1 reference

Europe PubMed Central

20 August 2017

Ahmad A Tarhini

7

1 reference

Europe PubMed Central

20 August 2017

John M Kirkwood

8

1 reference

Europe PubMed Central

20 August 2017

language of work or name

0 references

publication date

11 October 2013

1 reference

Europe PubMed Central

20 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

20 August 2017

19

1 reference

Europe PubMed Central

20 August 2017

23

1 reference

Europe PubMed Central

20 August 2017

6597-6604

1 reference

Europe PubMed Central

20 August 2017

U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

6 September 2017

Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

6 September 2017

Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

6 September 2017

A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

6 September 2017

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

6 September 2017

Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

6 September 2017

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

6 September 2017

Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

6 September 2017

Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

6 September 2017

Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

6 September 2017

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

6 September 2017

IL-8 expression in malignant melanoma: implications in growth and metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

6 September 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

6 September 2017

Enhanced expression of vascular endothelial growth factor in metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

6 September 2017

Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

14 September 2017

Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

28 September 2017

Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

26 June 2018

Analysis of survival by tumor response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

26 June 2018

A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

2 September 2018

Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

2 September 2018

A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

2 September 2018

Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

2 September 2018

Endotoxins induce and interferon alpha suppresses vascular endothelial growth factor (VEGF) production in human peripheral blood mononuclear cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

2 September 2018

Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

2 September 2018

Interferon-α-Induced Inhibition of B16 Melanoma Cell Proliferation: Interference with the bFGF Autocrine Growth Circuit

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859372

3 December 2018

Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24122792

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24122792

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/24122792

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/24122792

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/24122792

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful treatment of infantile hemangiomas with interferon-alpha-2b

1 reference

https://pubmed.ncbi.nlm.nih.gov/24122792

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth

1 reference

https://pubmed.ncbi.nlm.nih.gov/24122792

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b

1 reference

https://pubmed.ncbi.nlm.nih.gov/24122792

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/24122792

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-13-1414

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37383950&oldid=2103142646"